Biogen Inc (BIIB) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Total Cash From Operating Activities Chart for Biogen Inc

Biogen Inc (BIIB) operating cash flow for FY2025 was USD 2.2B, a -23.3% change from FY2024. Biogen Inc's operating cash flow moved from USD -7.5M in 1989 to USD 2.2B in 2025 over 36 years. Operating cash flow compound annual growth rate: 5-year CAGR of -12.2%, 10-year CAGR of -5.1%, 20-year CAGR of 4.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$30.48B
Implied Share Price
$206.28
Enterprise Value
$37.87B
Revenue (TTM)
$10.03B
EBITDA
$3.36B
Profit Margin
8.32%
Trailing P/E
36.77
Forward P/E
17.09
Price/Book (MRQ)
1.63
Price/Sales (TTM)
3.04
EV/EBITDA
17.70
EV/Revenue
3.78
Dividend Yield
—
Book Value
$127.61
Free Cash Flow (FY2025)
$2.05B
Free Cash Flow Yield
6.73%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.